• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Paronychia treatment Companies

    ID: MRFR/Pharma/1184-HCR
    80 Pages
    Kinjoll Dey
    September 2025

    Companies specifically dedicated to paronychia treatment may not be widespread, as this condition is typically managed by healthcare professionals using a combination of general wound care and, in some cases, prescription medications. However, companies producing relevant pharmaceuticals or products for wound care and infection management may be involved

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Paronychia treatment Market

    Paronychia Treatment Market

     


    Latest Paronychia Treatment Companies Updates:


    Bausch Health expands Jublia reach: In October 2023, Jublia, their topical solution for paronychia, received marketing authorization in Canada, expanding its availability beyond the US and Europe.


    Moberg Pharma strengthens MEA presence: Their agreement with Mundipharma in November 2020 grants them wider distribution of their topical nail disorder treatments throughout the Middle East and Africa.


    FDA approval for dabrafenib/trametinib: In June 2022, the FDA approved this combination therapy for treating a rare form of paronychia related to BRAF gene mutations, offering hope for patients with limited treatment options.


    List of Paronychia Treatment Key companies in the market:



    • GlaxoSmithKline plc

    • Perrigo New York, Inc.

    • Jonakayem Pharma Formulation Pvt. Ltd.

    • Glenmark Generics Ltd.

    • Teva Pharmaceutical Industries Ltd.

    • Fougera Pharmaceuticals Inc.

    • Eli Lilly Company